[CEO Interview] The Challenge of Creating a “Life & Time, as never seen before”: The Future of Urban Living Connected by BLUE FRONT SHIBAURA
BLUE FRONT SHIBAURA has emerged along the waterfront in Shibaura, Tokyo. In August 2025, CMIC Group relocated its headquarters to TOWER S, the first building in the complex. What inspired the effort to create new value while blending urban convenience with the richness of nature? CEO Nakamura discussed this vision with Mr. Eiji Kutsukake, Chairman of Nomura Real Estate Holdings.
Eiji Kutsukake Chair and Director, Nomura Real Estate Holdings, Inc.
Born in 1960 in Nagano, Japan. Graduated from the School of Political Science and Economics at Meiji University in 1984 and joined Nomura Securities the same year. He served as branch manager of the Shinjuku Nomura Building Branch and the Kyoto Branch, and later held positions including Executive Officer and Senior Managing Executive Officer. In 2012, he was appointed Executive Vice President of Nomura Securities. In 2014, he transferred to Nomura Real Estate Holdings, serving as Executive Vice President before becoming President & CEO in 2015. He was appointed Chairman of the Board in April 2023.
Kazuo Nakamura Ph. D. Representative Director, Chairman and CEO, CMIC HOLDINGS Co., Ltd.
Born in 1946 in Kofu City, Yamanashi Prefecture, Japan. Graduated from the Faculty of Pharmaceutical Sciences at Kyoto University in 1969 and completed the Doctoral Program at the Graduate School of Natural Science and Technology, Kanazawa University, in 2008, earning a Ph.D. in Pharmaceutical Sciences. In 1969, he joined Sankyo Co., Ltd. (now Daiichi Sankyo Co., Ltd.), where he served as project leader for the development of Mevalotin, a world-renowned blockbuster drug for the treatment of hyperlipidemia and familial hypercholesterolemia. After gaining extensive
experience in the pharmaceutical industry, he founded CMIC in 1992, Japan’s first CRO (Contract Research Organization). Under his leadership, CMIC established a comprehensive business model supporting the entire pharmaceutical value chain. Today, the company continues to evolve, aiming to contribute to the enhancement of individual health value.
Download to read the full article.
